emerg
reemerg
infecti
diseas
well
cancer
pose
great
global
health
impact
societi
vaccin
emerg
effect
treatment
prevent
reduc
burden
alreadi
develop
diseas
achiev
mean
activ
variou
compon
immun
system
gener
system
inflammatori
reaction
target
infecti
agent
diseas
cell
controlelimin
dna
virusbas
genet
vaccin
gain
signific
attent
past
decad
owe
develop
dna
manipul
technolog
allow
engin
recombin
viral
vector
encod
sequenc
foreign
antigen
immunogen
epitop
well
variou
immunomodulatori
molecul
despit
tremend
progress
past
year
mani
hurdl
still
remain
achiev
full
clinic
potenti
viralvector
vaccin
chapter
present
evolut
vaccin
live
attenu
firstgener
agent
recombin
dna
viralvector
vaccin
particular
emphasi
given
human
adenoviru
ad
av
borovjagin
et
al
av
borovjagin
et
al
av
borovjagin
et
al
develop
prophylact
therapeut
vaccin
ad
biolog
properti
relat
vaccin
develop
highlight
along
advantag
potenti
hurdl
overcom
particular
discuss
genet
modif
ad
capsid
protein
reduc
intrins
viral
immunogen
antigen
capsid
incorpor
effect
present
foreign
antigen
immun
system
modif
hexon
fiber
capsid
protein
ad
liver
detarget
select
retarget
cancer
cell
adbas
vaccin
carri
arm
transgen
immunostimulatori
function
immun
adjuv
oncolyt
ad
vector
new
therapeut
approach
cancer
final
combin
adenovir
vector
nonadenovir
vector
system
primeboost
strategi
immun
clinic
trial
involv
adbas
vaccin
perspect
field
develop
discuss
emerg
reemerg
infecti
diseas
well
cancer
pose
great
global
health
impact
societi
vaccin
emerg
effect
treatment
prevent
reduc
burden
alreadi
develop
diseas
achiev
mean
activ
variou
compon
immun
system
gener
system
inflammatori
reaction
target
infecti
agent
diseas
cell
control
elimin
dna
virusbas
genet
vaccin
gain
signific
attent
past
decad
owe
develop
dna
manipul
technolog
allow
engin
recombin
viral
vector
encod
sequenc
foreign
antigen
ag
immunogen
epitop
well
variou
immunomodulatori
molecul
emerg
result
parasitehost
coevolut
virus
vehicl
deliveri
express
agencod
sequenc
may
also
function
immun
adjuv
enhanc
immun
respons
transgeneexpress
ag
despit
tremend
progress
past
year
mani
hurdl
still
remain
develop
virusbas
vaccin
effect
clinic
use
human
adenoviru
ad
emerg
one
top
candid
viral
vector
vaccin
develop
owe
primarili
rel
low
pathogen
genet
safeti
lack
host
genom
integr
step
replic
cycl
attract
featur
ad
vaccin
applic
includ
strong
immuneadjuv
properti
highli
effici
infect
variou
cell
type
vast
transgen
incorporationclon
capac
although
chapter
primarili
focus
use
human
ad
develop
prophylact
therapeut
vaccin
applic
viral
vector
vaccin
develop
also
briefli
discuss
present
vaccin
first
accord
deliveri
systemsvir
vector
type
regard
clinic
applic
ie
prophylact
therapeut
lead
detail
descript
ad
vaccin
vector
taxonomi
serotyp
divers
well
genom
molecular
structur
ad
biolog
properti
relat
potenti
role
vaccin
vector
highlight
along
advantag
potenti
hurdl
vaccin
develop
along
line
discuss
detail
ag
capsid
incorpor
strategi
aim
gener
robust
humor
agspecif
immun
respons
circumv
vectorspecif
preexist
immun
substanti
attent
devot
ad
vector
carri
arm
transgen
immunostimulatori
function
vaccin
adjuv
strategi
illustr
use
develop
therapeut
vaccin
cancer
retarget
ad
vector
specif
cell
surfac
receptor
detarget
natur
receptor
coxsackieadenoviru
receptor
discuss
along
underli
molecular
technolog
mean
augment
ad
infect
cancer
cell
improv
gene
transfer
effici
also
describ
vaccin
strategi
involv
combin
ad
vector
nonad
vaccin
system
well
primeboost
strategi
immun
commonli
use
immunocompet
anim
model
immunotherapi
studi
preclin
evalu
adenovir
vaccin
lastli
briefli
discuss
clinic
trial
involv
adbas
vaccin
perspect
field
develop
invent
virusbas
vaccin
date
back
year
edward
jenner
made
groundbreak
discoveri
pu
cowpoxinfect
patient
elicit
crossprotect
subject
much
virul
human
diseas
smallpox
jenner
term
vaccin
come
latin
word
vaccinu
translat
pertain
cow
reflect
histori
discoveri
although
begin
twentieth
centuri
vaccin
alreadi
wide
use
prevent
infecti
diseas
diphtheria
rabi
plagu
noth
cow
origin
term
remain
tradit
concept
vaccin
appli
induct
protect
immun
given
pathogen
host
achiev
intent
exposur
natur
surrog
pathogen
ag
deriv
pathogen
sourc
ag
vari
welldefin
recombin
protein
natur
protein
isol
pathogen
whole
pathogen
firstgener
vaccin
includ
live
attenu
vaccin
prepar
pathogen
virus
yellow
fever
measl
mump
rubella
bacteria
salmonella
enterica
enterica
reduc
virul
treatment
virul
strain
temperatur
chemic
allow
gener
inactiv
kill
vaccin
includ
influenza
cholera
polio
hepat
rabi
vaccin
well
toxoid
formaldehydeinactiv
toxin
natur
produc
pathogen
repres
diphtheria
tetanu
vaccin
pathogenstoxin
vaccin
longer
infectioustox
ie
biolog
safe
immunogen
properti
retain
advanc
basic
knowledg
immunolog
along
develop
recombin
dna
technolog
past
year
prompt
extens
effort
vaccin
develop
led
secondgener
vaccin
includ
recombin
vaccin
recombin
dna
technolog
substanti
expand
repertoir
vaccin
type
may
differ
regard
form
immunolog
target
immunogen
rout
deliveri
recombin
vaccin
compris
sever
distinct
class
subunit
vaccin
typic
obtain
genet
clone
express
immunogen
protein
individu
subunitsdomain
use
variou
express
system
bacteri
yeast
mammalian
conjug
vaccin
special
type
subunit
vaccin
use
ag
toxoid
conjug
polysaccharid
enhanc
immunogen
haemophilu
influenza
type
b
vaccin
dna
nake
dna
vaccin
viralvector
vaccin
latter
instanc
foreign
ag
express
host
cell
upon
deliveri
recombin
dna
molecul
code
ag
west
nile
viru
experiment
vaccin
alarcon
et
al
contrast
nake
dna
vaccin
also
known
thirdgener
vaccin
virusbas
vaccin
use
recombin
viral
vector
natur
vehicl
deliv
foreign
agencod
sequenc
term
vector
vaccin
gener
use
live
recombin
virus
bacteria
repres
natur
carrier
vector
capabl
incorpor
transgen
pathogen
express
host
without
caus
ill
viral
vector
provid
substanti
effici
ag
deliveri
method
known
transduct
compar
nake
dna
besid
nake
dnabas
vaccin
found
unabl
induc
strong
cellular
immun
respons
human
contrast
ag
deliv
context
viral
vector
immunogen
ag
deliv
protein
agencod
nake
dna
primarili
due
abil
mammalian
innat
immun
system
recogn
virus
danger
signal
tolllik
receptor
lead
generationintegr
innat
adapt
immun
respons
pronounc
immun
efficaci
viru
virusbas
vaccin
contain
agcod
sequenc
replac
gene
requir
viral
replic
thu
replic
defici
recent
vaccin
design
expand
toward
replicationcompet
viral
vector
advantag
replic
virus
vector
dramat
amplif
transgen
express
excess
viral
dna
replic
enhanc
immun
effici
allow
decreas
vaccin
dose
disadvantag
includ
cell
lysi
typic
occur
upon
infect
ultim
step
viral
life
cycl
may
reduc
durat
transgen
express
vaccin
efficaci
furthermor
develop
vaccin
base
replicationcompet
viral
vector
requir
adequ
anim
model
immunocompet
also
fulli
permiss
replic
given
viru
may
avail
cost
permiss
import
benefit
use
virusbas
vaccin
abil
modul
effici
celltyp
specif
agencod
transgen
deliveri
achiev
alter
natur
tropism
viral
vector
make
possibl
effici
specif
transduct
specif
cell
populationcel
type
cancer
agpres
cell
apc
variou
strategi
transduct
retarget
viral
vector
develop
recent
year
larg
varieti
viral
vector
system
advantag
disadvantag
use
vaccin
develop
detail
descript
vector
system
provid
sect
natur
viral
infect
viral
vector
capabl
induc
strong
innat
well
adapt
immun
respons
establish
longterm
immunolog
memori
preexist
immun
pei
particularli
agspecif
antibodi
ab
mani
human
virus
typic
found
patient
significantli
compromis
clinic
efficaci
correspond
viral
vector
use
vaccin
gene
therapi
applic
mani
strategi
develop
circumv
pei
virusbas
vector
describ
section
low
immunogen
ag
may
requir
complex
regimen
vaccin
involv
primeboost
approach
may
combin
two
differ
vaccin
type
repeat
deliveri
ag
dna
vaccin
follow
viral
vaccin
vice
versa
mani
contemporari
vaccin
design
use
polyval
approach
allow
immun
one
ag
serolog
variant
serotyp
given
pathogen
even
sever
differ
pathogen
simultan
optim
vaccin
protocol
develop
consid
variou
factor
dose
rout
administr
type
prime
boost
vector
number
boost
immun
time
convent
prophylact
ie
prevent
vaccin
infecti
diseas
highli
effect
elimin
drastic
reduc
incid
mani
lifethreaten
diseas
smallpox
poliomyel
vaccin
administ
host
prior
encount
pathogen
infecti
agent
virus
bacteria
singl
except
rabi
vaccin
develop
pasteur
year
ago
administ
exposur
viru
howev
applic
therapeut
vaccin
recent
rise
owe
signific
technolog
develop
comprehens
understand
immun
system
unlik
prophylact
vaccin
achiev
diseaseprevent
effect
gener
humor
immun
respons
therapeut
vaccin
often
function
robust
tcell
respons
key
viral
ag
contribut
humor
respons
therapeut
efficaci
vaccin
depend
target
pathogen
diseas
therapeut
vaccin
develop
develop
variou
indic
includ
persist
infect
hepat
b
c
virus
hbv
hcv
human
papillomaviru
hpv
human
immunodefici
viru
hiv
tuberculosi
malaria
well
noninfecti
chronic
diseas
autoimmun
diseas
gastric
ulcer
prioncaus
mad
cow
diseas
creutzfeldtjakob
diseas
alzheim
diseas
variou
cancer
immunolog
control
persist
viral
infect
hpv
hbv
hcv
caus
longterm
damag
host
infect
organ
becom
primari
goal
therapeut
vaccin
effort
hpv
caus
obviou
diseas
set
infect
host
risk
develop
cancer
similar
hbv
hcv
hpv
hbv
hcv
elimin
immun
system
acut
infect
sometim
chronic
phase
persist
hiv
infect
prove
challeng
although
variou
contribut
factor
integr
hiv
dna
genom
virustarget
immun
cell
appear
play
determin
role
finzi
et
al
unlik
prophylact
vaccin
induct
effector
immun
respons
pathogen
primari
requir
vaccin
efficaci
therapeut
vaccin
chronic
infect
cancer
requir
overcom
two
major
obstacl
achiev
efficaci
induct
effector
immun
respons
host
may
develop
toler
pathogen
cancer
ag
overcom
variou
immun
evas
mechan
employ
chronic
infect
progress
cancer
furthermor
therapeut
vaccin
administ
patient
suppress
immun
due
prior
chemoandor
radiat
therapi
treatment
alreadi
develop
diseas
background
vaccin
develop
gone
long
way
achiev
success
control
fulli
erad
number
fatal
infecti
diseas
howev
despit
rapid
progress
recombin
dna
technolog
effect
immun
mani
human
infecti
noninfecti
diseas
remain
challeng
due
immun
evas
achiev
correspond
pathogen
disabl
immun
system
compon
crucial
vaccin
mechan
warrant
effort
improv
recombin
vaccin
vaccin
strategi
regard
viral
vector
provid
import
advantag
recombin
dnabas
vector
two
major
type
vector
system
deliveri
recombin
dna
rdna
human
tissu
nonvir
viral
luo
et
al
viral
vector
provid
highest
gene
transfer
transgen
express
effici
vivo
main
impetu
use
virusbas
vector
report
rdnabas
clinic
protocol
luo
et
al
wide
varieti
anim
virus
employ
develop
viral
vector
system
tabl
extens
knowledg
replic
packag
assembl
requir
variou
virus
allow
gener
replicationcompet
replicationdefici
nonrepl
viral
vector
furthermor
genet
manipul
viral
genom
aim
modif
viral
natur
tropism
achiev
tissueor
celltyp
specif
viral
infect
replic
time
effici
transgen
express
intracellular
traffick
transgeneencod
product
recent
becom
possibl
combin
safeti
specif
high
level
product
make
viral
vector
lead
choic
express
foreign
gene
experiment
commerci
applic
levin
adenoassoci
viru
aav
member
dependoviru
genu
parvovirida
famili
includ
vast
seri
small
virus
singlestrand
dna
genom
fig
virus
infect
numer
speci
mammal
includ
human
bern
linden
aav
virion
smallest
among
gene
therapi
vector
capsid
icosahedr
symmetri
diamet
nm
compos
protein
encod
singl
gene
cap
gene
encapsid
aav
genom
linear
singlestrand
dna
either
posit
neg
polar
typic
aav
prepar
mixtur
virion
contain
dna
posit
neg
polar
bern
compar
studi
use
lung
cancer
cell
line
identifi
effect
transduc
among
five
adenoassoci
viru
serotyp
chen
et
al
commonli
use
serotyp
transgen
deliveri
although
major
human
popul
seroposit
aav
signific
advers
event
either
pretrial
efficaci
studi
clinic
trial
involv
aav
observ
maguir
et
al
bainbridg
et
al
wildtyp
wt
aav
integr
specif
region
human
chromosom
upon
host
cell
infect
kotin
et
al
wherea
abil
sitespecif
integr
lost
raav
possibl
due
delet
viral
rep
gene
although
integr
gene
deliveri
system
allow
stabl
transgen
express
episom
one
integr
foreign
dna
cellular
chromosom
dna
associ
risk
insert
mutagenesi
turn
may
caus
malign
cell
transform
romano
therapeut
transgen
intern
promot
regul
transgen
express
raavbas
vector
replac
viral
rep
cap
gene
fig
bartel
et
al
although
aav
vector
less
immunogen
adenovir
vector
low
transduct
effici
certain
tissu
inabl
target
deliveri
specif
cell
type
rel
low
transgenecarri
capac
kb
depend
helper
viru
propag
limit
util
vector
human
clinic
applic
howev
sever
clinic
trial
aav
perform
exampl
clinic
trial
advanc
cancer
patient
conduct
china
evalu
safeti
adopt
cytotox
lymphocyt
ctl
gener
cocultur
dendrit
cell
dc
transduc
raav
encod
carcinoembryon
ag
cea
studi
demonstr
infus
ceaspecif
ctl
well
toler
show
sever
advers
reaction
cancer
patient
di
et
al
two
phase
clinic
trial
one
one
phase
ii
clinic
trial
antitrypsin
gene
therapi
shown
promis
result
howev
level
antitrypsin
target
rang
indic
need
increas
dose
vector
andor
gene
express
level
achiev
therapeut
rang
mueller
flott
ad
discov
human
adenoid
tissu
ender
et
al
nonenvelop
dna
virus
carri
linear
doublestrand
dna
kb
size
fig
current
typesserotyp
adenovirida
famili
compos
genera
capabl
infect
human
larg
number
differ
anim
speci
known
human
ad
belong
mastadenoviru
genu
character
serotyp
distinct
speciessubgroup
ag
respons
acut
respiratori
diseas
children
variabl
number
epidem
conjunct
gastroenter
giacca
zacchigna
natur
tropism
human
ad
respiratori
epithelium
conjunctiva
mainli
determin
mode
transmiss
rather
molecular
characterist
viru
inde
car
receptormedi
cell
infect
ad
ubiquit
express
human
cell
type
sustain
adenovir
infect
replic
regardless
prolif
state
law
davidson
extens
character
ad
type
type
type
member
c
subgroup
ad
first
gener
lack
second
gener
devoid
third
gener
lack
earli
gene
itr
invert
termin
repeat
packag
signal
serotyp
use
engin
firstgener
ad
vector
sinc
associ
sever
diseas
human
therefor
suitabl
vivo
applic
anoth
attract
properti
ad
high
effici
exploit
cellular
machineri
synthes
viral
mrna
virusspecif
protein
given
consider
surpris
ad
vector
becom
focu
vast
seri
anim
clinic
experiment
sinc
second
half
giacca
zacchigna
attribut
ad
well
viral
vector
describ
detail
tabl
three
gener
replicationincompet
ad
describ
date
fig
firstgener
fg
ad
delet
gene
becom
substitut
express
cassett
typic
consist
promot
drive
therapeut
gene
polyadenyl
signal
danthinn
imperial
helper
cell
contain
genom
copi
entir
region
plu
gene
provid
tran
protein
essenti
initi
viral
replic
loui
et
al
human
embryon
kidney
cell
line
stabli
transfect
express
viral
protein
wide
use
helper
cell
line
product
recombin
replicationdefici
ad
stock
danthinn
imperial
secondgener
sg
ad
vector
develop
lack
gene
addit
gene
fig
sg
vector
expect
show
prolong
transgen
persistenceexpress
due
fewer
encod
adspecif
ag
elicit
vectorassoci
immun
respons
immun
respons
virusspecif
gene
decreas
durat
addeliv
therapeut
transgen
express
ctlmediat
elimin
adtransduc
host
cell
bessi
et
al
liu
muruv
sg
vector
propag
depend
helper
cell
line
provid
tran
miss
function
gene
requir
ad
dna
replic
transcript
regul
ad
gene
helper
cellprovid
function
also
includ
transit
earli
late
phase
viral
gene
express
viral
mrna
transport
host
protein
synthesi
shutoff
assembl
virion
morsi
caskey
delet
addit
genom
region
sg
ad
vector
howev
circumv
problem
shortterm
transgen
express
plausibl
due
immunogen
inflammatori
potenti
residu
ad
gene
product
sg
vector
furthermor
express
therapeut
gene
sg
vector
reduc
compar
fg
vector
probabl
due
miss
regulatori
function
gene
product
directli
indirectli
upregul
express
virusspecif
gene
fg
wt
ad
giacca
zacchigna
thirdgener
replicationdefici
ad
vector
fig
character
complet
elimin
viral
code
region
leav
invert
termin
repeat
itr
transgen
express
cassett
psi
packag
signal
advantag
vector
lie
substanti
lower
immunogen
product
high
viral
titer
cell
line
howev
vector
name
gutless
helper
depend
replic
depend
entir
coinfect
packag
cell
line
helper
vector
produc
tran
requir
ad
protein
vector
also
describ
high
capac
accommod
dna
sequenc
kb
thu
allow
deliveri
larg
multipl
transgen
alba
et
al
brunettipierri
ng
anoth
type
ad
vector
use
particularli
cancer
gene
therapi
approach
condit
replic
ad
crad
also
refer
oncolyt
ad
crad
infect
replic
spread
kill
cancer
cell
natur
lytic
mechan
refer
oncolysi
gener
principl
vector
base
render
viral
replic
cancer
select
mutat
introduc
ad
delet
gene
partial
base
pair
bp
delet
gene
ad
gene
product
trigger
prolifer
infect
cell
essenti
ad
replic
function
induc
degrad
tumor
suppressor
result
block
apoptosi
along
activ
cell
cycl
signal
mutat
would
therefor
make
ad
unabl
product
replic
normal
cell
carri
function
contrast
crad
would
replic
mani
cancer
cell
signal
disabl
normal
tumor
suppress
mechan
inact
high
percentag
tumor
cell
possess
defect
thu
suscept
kill
crad
bischoff
et
al
known
origin
call
barker
berk
anoth
type
crad
carri
abovement
bp
delet
prbbind
domain
show
impair
replic
normal
cell
prbbind
function
requir
displac
cellular
transcript
factor
complex
tumor
suppressor
prb
induc
prolif
state
infect
cell
howev
defect
complement
prb
signal
defect
number
prbdefect
cancer
make
crad
known
fueyo
et
al
anoth
crad
similar
delet
heis
et
al
cancer
select
clinic
util
adbas
vector
improv
gener
vector
lose
nativ
tropism
andor
acquir
cell
tissu
specif
transduct
genet
modif
viral
capsid
protein
besid
target
ad
capsid
modif
show
util
imag
vaccin
develop
applic
tabl
summar
featur
ad
capsid
modif
applic
identifi
human
ad
serotyp
extens
use
gene
therapi
applic
scientist
taken
altern
approach
convent
express
immun
ag
context
viral
vector
approach
embodi
genet
incorpor
ag
viral
capsid
innov
paradigm
base
present
ag
compon
viral
capsid
achiev
genet
fusion
incorpor
viral
capsid
protein
rather
vectorexpress
transgen
vaccin
design
use
ad
vector
display
ag
capsid
surfac
known
ag
capsid
incorpor
strategi
whole
ag
stevenson
et
al
krasnykh
et
al
kanerva
et
al
kawakami
et
al
argglyasp
rgd
motif
incorpor
hi
loop
fiber
knob
form
cdcrgdcfc
peptid
reduc
natur
liver
tropism
vivo
factor
xmediat
liver
uptak
nicol
et
al
incorpor
integrinbind
peptid
cterminu
hi
loop
local
knob
context
chimera
fiber
enhanc
cancer
cell
transduct
detarget
car
ablat
car
tropism
improv
gene
transfer
glioma
borovjagin
et
al
tyler
et
al
continu
immunogen
peptid
incorpor
viral
capsid
offer
potenti
advantag
vaccin
applic
owe
process
capsidincorpor
ag
exogen
pathway
nativ
ad
capsid
protein
ag
could
accru
immunostimulatori
potenti
strong
humor
respons
incorpor
ag
similar
one
induc
ad
capsid
protein
could
result
adjuv
function
ad
vector
ag
capsid
incorpor
strategi
also
appli
human
rhinoviru
vector
vaccin
hiv
chimer
human
rhinoviru
hiv
shown
stimul
immun
smith
et
al
addit
combinatori
librari
human
rhinoviru
capsidincorpor
glycoprotein
epitop
shown
induc
ab
activ
mimic
nab
effect
arnold
et
al
preclin
clinic
develop
adbas
hiv
vaccin
progress
faster
develop
vector
system
human
rhinoviru
owe
tremend
flexibl
ad
vector
gener
exceed
rhinoviru
system
instanc
sinc
human
rhinoviru
rel
small
rna
viru
human
rhinoviru
platform
murugesan
et
al
matsui
et
al
fiber
modif
replac
knob
part
shaft
phagederiv
fibritin
fuse
ligand
select
target
cell
dc
cell
immunotherapi
applic
krasnykh
et
al
belousova
et
al
fiber
modif
use
fiberfibritin
chimera
fuse
singlechain
ab
affibodi
aureu
protein
fcbind
domain
permit
detarget
target
hepatocyt
evas
kupffer
cell
scaveng
prill
et
al
display
copi
singl
antigen
epitop
smith
et
al
contrast
ad
vector
capsid
platform
could
allow
incorpor
epitop
four
distinct
structur
proteinslocal
includ
hexon
abe
et
al
fiber
penton
base
pix
capsid
protein
fig
matthew
nemerow
et
al
matthew
et
al
although
fiber
kraus
et
al
shiratsuchi
et
al
sharma
et
al
penton
base
kraus
et
al
pix
kraus
et
al
seregin
et
al
b
util
ag
capsid
incorpor
major
ag
capsid
incorpor
strategi
endeavor
major
capsid
protein
hexon
fig
hexon
abund
structur
protein
ad
capsid
account
total
protein
mass
rux
et
al
van
oostrum
burnett
sequenc
analysi
hexon
protein
differ
ad
speci
reveal
addit
evolutionarili
conserv
region
also
nonconserv
hypervari
region
hvr
contain
serotypespecif
epitop
rux
et
al
crawfordmiksza
schnurr
loop
top
hvr
pliabl
modif
genet
engin
short
heterolog
peptid
incorpor
within
hvr
hexon
without
affect
virion
stabil
biolog
characterist
subset
modifi
loop
expos
surfac
capsid
hvr
util
vign
et
al
wu
et
al
worgal
et
al
worgal
et
al
mcconnel
et
al
matthew
et
al
palma
et
al
adbas
vaccin
develop
use
ag
capsid
incorpor
strategi
test
preclin
variou
diseas
set
crompton
et
al
worgal
et
al
worgal
et
al
kraus
et
al
mcconnel
et
al
matthew
et
al
matthew
gu
et
al
one
first
exampl
ag
capsid
incorpor
use
context
ad
studi
crompton
et
al
eightamino
acid
sequenc
capsid
protein
polioviru
type
insert
two
distinct
region
hexon
protein
without
affect
propag
effici
one
result
chimer
vector
tissu
cultur
antiserum
rais
recombin
ad
vector
polio
epitop
insert
specif
recogn
capsid
protein
polio
type
similar
studi
demonstr
epitop
could
incorpor
hexon
hvr
reclassifi
without
perturb
viral
viabil
major
biolog
characterist
replic
thermost
nativ
infect
accord
studi
appear
surfac
expos
incorpor
within
wu
et
al
effort
creat
multival
vaccin
vector
use
ag
capsid
incorpor
strategi
target
incorpor
antigen
epitop
compar
flexibl
insert
capac
hexon
modifi
incorpor
ident
epitop
increment
increas
size
rang
amino
acid
within
local
viabl
vector
produc
incorpor
amino
acid
plu
acid
linker
addit
viabl
vector
produc
incorpor
amino
acid
plu
acid
linker
found
permiss
allow
incorpor
peptid
amino
acid
model
ag
surfac
expos
evidenc
wholeviru
elisa
analysi
vivo
immun
vector
demonstr
agspecif
immun
respons
matthew
et
al
although
vivo
respons
evalu
context
pei
possibl
vector
would
inde
escap
pei
matthew
et
al
along
line
studi
evalu
abil
vector
express
hiv
transgen
induc
agspecif
immun
respons
presenc
preimmun
condit
overcom
limit
impos
pei
author
construct
vector
carri
modif
hexon
studi
character
variou
immunolog
paramet
associ
vector
vector
neutral
acquisit
adapt
immun
respons
comparison
protect
immun
regard
adluc
luciferas
protein
express
transgen
ad
region
adhisluc
epitop
present
region
luciferas
protein
express
transgen
adendaaaluc
vector
contain
three
amino
acid
mutat
express
luciferas
protein
administ
mice
im
hexonmodifi
vector
adhisluc
gener
lowest
neutral
activ
significantli
lower
gener
adluc
week
adendaaaluc
vector
week
individu
neutral
activ
respons
adhisluc
immun
significantli
lower
respons
immun
adluc
studi
support
concept
modifi
hexon
thwart
nab
promot
cellular
immun
respons
find
indic
chang
immunogen
epitop
necessari
avoid
neutral
preexist
nab
abe
et
al
studi
first
kind
membran
proxim
ectodomain
region
mper
hiv
protein
incorpor
hexon
alon
combin
genom
incorpor
gag
transgen
characterist
result
vector
gag
respect
growth
kinet
thermost
remain
unchang
compar
peptid
ag
capsidincorpor
vector
matthew
et
al
li
et
al
demonstr
incorpor
mper
epitop
within
substanti
detriment
vector
biolog
matthew
et
al
li
et
al
studi
first
demonstr
diseasespecif
ag
could
incorpor
within
importantli
data
demonstr
humor
antihiv
respons
mice
immun
hexonmodifi
ad
vector
immun
mperdisplay
vector
allow
boost
contrast
immun
adcmvgag
vector
possibl
gag
vector
elicit
less
immun
respons
like
incorpor
mper
epitop
within
vector
reduc
immunogen
vector
find
notabl
fulli
explor
potenti
use
ag
capsid
incorpor
strategi
followup
studi
gener
adbas
multival
vector
potenti
util
vaccin
sever
strain
organ
two
distinct
organ
attempt
multival
vaccin
base
ad
gener
display
ag
within
hexon
studi
focus
gener
proofofconcept
vector
ultim
result
develop
multival
vaccin
vector
display
dual
ag
within
hexon
singl
ad
virionparticl
novel
vector
util
hexon
incorpor
site
seven
amino
acid
epitop
eldkwa
hiv
mper
region
fig
combin
incorpor
multival
capsidbas
vaccin
incorpor
hiv
ag
along
within
singl
ad
virionparticl
gener
hiv
epitopespecif
humor
immun
respons
mice
report
illustr
multival
capsidbas
vaccin
viabl
immunogen
present
differ
antigen
within
singl
ad
virionparticl
immedi
futur
like
viral
vectorbas
vaccin
becom
common
clinic
intervent
therefor
becom
increasingli
import
design
vector
overcom
pei
thacker
et
al
seregin
amalfitano
toward
end
rare
nonhuman
ad
serotyp
genet
modifi
vaccin
develop
chimer
ad
vector
could
consist
subport
vector
genom
replac
genom
portion
anoth
altern
serotyp
thu
creat
chimer
ad
vector
altern
extrem
approach
entir
ad
vector
genom
could
compos
gene
deriv
sole
altern
ad
serotyp
noureddini
curiel
seregin
amalfitano
abbink
et
al
youil
et
al
robert
et
al
liu
et
al
mccoy
et
al
ad
hexon
fiber
protein
manipul
genet
chimer
strategi
primarili
protein
known
target
vector
nab
molinierfrenkel
et
al
roy
et
al
wu
et
al
gall
et
al
sever
chimer
fiberand
hexongener
strategi
employ
tabl
seregin
amalfitano
nab
gener
hexon
hvr
account
antiad
nab
respons
play
critic
role
vector
clearanc
therebi
reduc
therapeut
efficaci
vaccin
vector
import
hvr
nab
epitop
remain
unclear
relat
serotyp
yuan
et
al
therefor
exact
map
nab
epitop
hvr
may
necessari
improv
chimer
vector
alba
et
al
one
first
studi
chimer
vector
construct
report
replac
nativ
hexon
gene
counterpart
sequenc
gall
et
al
studi
launch
point
develop
chimer
vector
anoth
studi
chimer
adenovir
vector
construct
replac
hexon
gene
chimer
vector
success
rescu
helper
cell
line
significantli
slower
growth
profil
compar
wt
vector
indic
hexon
capabl
capsid
incorpor
support
encapsid
viral
genom
lower
effici
nativ
hexon
gene
transfer
effici
hela
cell
also
lower
host
neutral
studi
demonstr
nab
gener
immun
mice
crossneutr
context
vitro
infect
hela
cell
therefor
preimmun
mice
one
two
type
vector
prevent
subsequ
infect
type
clearli
demonstr
substitut
hexon
hexon
circumv
host
neutral
wu
et
al
recent
along
line
anoth
chimer
ad
vector
gener
replac
hexon
gene
hexon
gene
report
tabl
tian
et
al
chimer
vector
success
gener
cell
hexoncontain
particl
abl
encapsid
viral
genom
function
effici
host
vector
neutral
respons
studi
demonstr
nab
produc
balbc
mice
infect
vector
specif
protein
vitro
therefor
preimmun
mice
one
vector
significantli
prevent
subsequ
inl
infect
vector
vivo
mark
contrast
preimmun
mice
either
prevent
subsequ
infect
vector
tian
et
al
replac
sequenc
seven
hvr
hexon
rare
serotyp
result
chimer
vector
capabl
evad
pei
preclin
studi
mice
rhesu
monkey
robert
et
al
chimer
vector
seven
hvr
substitut
induc
level
antiag
immun
respons
mice
pei
mice
contrast
replac
singl
hvr
provid
slight
enhanc
antiag
immun
respons
nonchimer
vector
studi
underway
determin
epitop
nab
vector
recent
studi
suggest
nab
respons
may
focus
one
specif
hvr
abe
et
al
crawfordmiksza
schnurr
chimer
vector
subset
hvr
substitut
hexon
hvr
construct
use
assess
potenti
individu
hexon
hvr
epitop
nab
partial
hvrchimer
vector
evalu
nab
assay
immunogen
studi
without
pei
variou
studi
demonstr
nab
target
sever
hvr
indic
need
replac
hvr
optim
evas
immun
bradley
et
al
liver
sequestr
vector
anoth
substanti
drawback
hinder
system
applic
therapi
previou
studi
demonstr
human
coagul
factor
x
fx
bind
hexon
direct
interact
gla
domain
hexon
hvr
lead
liver
uptakesequestr
follow
system
deliveri
waddington
et
al
kalyuzhniy
et
al
bind
affin
fx
vari
among
ad
serotyp
may
account
differ
hepatocyt
transduct
effici
previous
observ
vivo
bind
factor
x
highest
affin
weak
bind
observ
hexonfx
interact
demonstr
multipl
human
ad
serotyp
show
divers
affin
level
domain
amino
acid
sequenc
hvr
integr
highaffin
interact
fx
howev
sever
aspect
bind
mechan
remain
uncertain
alba
et
al
util
vector
deriv
entir
altern
human
ad
serotyp
includ
also
shown
great
promis
particularli
term
abil
deliv
transgen
abbink
et
al
liu
et
al
liu
et
al
barouch
et
al
vector
base
ad
normal
infect
nonhuman
speci
also
shown
great
promis
nonhuman
ad
vector
develop
numer
speci
includ
canin
bovin
porcin
chimpanze
exampl
vector
recent
develop
chimpanze
ad
adc
initi
adc
vector
gain
attent
sinc
human
sera
fail
significantli
neutral
roy
et
al
notabl
unlik
serotyp
mutant
easili
propag
vitro
vector
express
sar
coronaviru
ag
elicit
higher
band
tcell
respons
compar
vector
carri
transgen
mice
pei
addit
promis
result
seen
vector
anoth
infecti
diseas
regard
singl
inject
encod
ebola
glycoprotein
provid
protect
lethal
challeng
unlik
correspond
vector
import
note
sever
ad
epitop
recogn
cell
conserv
among
broad
rang
human
nonhuman
primatederiv
ad
therefor
possibl
cell
patient
pei
also
recogn
vector
deriv
altern
ad
speci
calcedo
et
al
leen
et
al
tang
et
al
joshi
et
al
sinc
nab
bovin
report
human
evalu
vaccin
applic
mous
model
singl
immun
encod
ha
ag
influenza
induc
greater
level
agspecif
cellular
immun
correspond
vector
properti
compromis
pei
singh
et
al
importantli
mice
pei
receiv
primeboost
regimen
vector
encod
ha
fulli
protect
lethal
flu
viru
challeng
contrast
mice
treat
homolog
primeboost
regimen
protect
consequ
ad
nonhuman
speci
may
induc
strong
respons
provid
immun
protect
compar
superior
retain
protect
potenti
presenc
pei
use
altern
serotyp
ad
thu
allow
improv
induct
immun
respons
vector
readministr
host
pei
abbink
et
al
liu
et
al
mccoy
et
al
result
earlier
studi
altern
serotyp
vector
test
patient
popul
hiv
vaccin
develop
barouch
et
al
addit
human
clinic
trial
evalu
vaccin
agent
hiv
initi
spite
benefit
associ
use
altern
serotyp
ad
vector
vector
sever
limit
includ
likelihood
caus
advers
effect
human
one
limit
altern
ad
serotyp
usag
unabl
induc
adequ
level
transgen
express
infect
cell
less
amen
largescal
purif
thacker
et
al
respect
ad
immun
respons
human
evolv
continu
exposur
popul
human
ad
speci
oppos
ad
speci
infect
nonhuman
host
consequ
possibl
human
system
innat
immun
react
capsid
protein
nonhuman
ad
speci
differ
way
also
plausibl
human
immun
system
induc
robust
innat
respons
challeng
differ
xenotyp
rare
serotyp
ad
upon
exposur
ad
serotyp
nativ
human
recent
demonstr
innat
immun
respons
capsid
protein
altern
serotyp
ad
substanti
robust
compar
case
caus
toxic
anim
model
abbink
et
al
appledorn
et
al
hartman
et
al
hensley
et
al
altern
serotyp
vector
intrins
differ
tropism
result
quit
differ
biodistribut
vector
vivo
last
decad
vector
proven
safe
human
anim
knowledg
gain
safeti
studi
must
taken
account
test
chimer
altern
serotypebas
vector
major
current
ad
vaccin
candid
repres
transgeneexpress
vector
commonli
engin
express
foreign
gene
insert
earli
e
region
ad
genom
small
ertl
gene
region
essenti
viral
replic
major
ad
vector
lack
replic
defici
huang
hear
weinberg
ketner
jone
shenk
substanti
amount
research
perform
replicationdefici
vector
human
anim
show
promis
sever
case
sullivan
et
al
studi
replic
ad
vaccin
difficult
hostanim
model
system
must
support
ad
replic
vaccin
evalu
condit
recapitul
intend
use
human
deal
et
al
mice
support
human
ad
replic
howev
syrian
hamster
thoma
et
al
cotton
rat
dog
pig
monkey
chimpanze
partial
support
replic
human
ad
vector
anim
therefor
offer
fulli
immunocompet
model
system
exploit
evalu
replic
vaccin
thoma
et
al
pacini
et
al
chengalvala
et
al
jogler
et
al
lubeck
et
al
klessig
grodzick
cotton
rat
syrian
hamster
extens
util
evalu
replic
properti
oncolyt
ad
vector
thoma
et
al
toth
et
al
dog
typic
use
character
adbas
vaccin
chengalvala
et
al
respect
evalu
replic
vector
context
primat
model
difficult
assess
vaccin
efficaci
translat
vivo
find
human
clinic
context
due
differ
primat
human
immun
system
replicationcompet
ad
serotyp
express
hbv
surfac
ag
hbsag
use
prime
hbsag
boost
hbsag
two
chimpanze
via
oral
administr
lubeck
et
al
primari
immun
chimpanze
shed
vaccin
viru
week
develop
ab
suggest
success
replic
anim
one
chimpanze
develop
transient
seroposit
hbsag
prime
chimpanze
develop
modest
ab
titer
boost
immun
third
chimpanze
prime
wt
boost
develop
hbsag
ab
hbsag
chimpanze
protect
acut
clinic
diseas
infect
evid
develop
ab
hbv
core
protein
respons
hbv
challeng
anim
seroconvert
along
unimmun
control
becam
clinic
infect
hbv
lubeck
et
al
three
human
particip
phase
vaccin
trial
immun
hbsag
vaccin
exhibit
advers
effect
shed
viru
day
postvaccin
evid
persontoperson
spread
despit
fact
patient
show
signific
increas
ab
none
gener
ab
hbsag
tacket
et
al
protect
diseas
infect
chimpanze
regardless
lack
seroconvers
human
suggest
potenti
valu
use
oral
enter
vaccin
rad
induc
humor
immun
respons
foreign
pathogen
vaccin
infecti
diseas
vaccin
infecti
diseas
current
licens
use
patient
includ
heatinactiv
kill
whole
organ
vaccin
microbi
extract
purifi
recombin
protein
dna
vaccin
viruslik
particl
vlp
recombin
virus
mani
diseas
control
essenti
erad
owe
vaccin
goal
gener
commun
immun
wide
varieti
diseas
remain
elus
due
number
problem
associ
current
vaccin
substanti
amount
time
research
effort
direct
toward
determin
strain
influenza
flu
includ
flu
vaccin
year
year
vaccin
match
quit
close
current
diseasecaus
strain
flu
sometim
despit
research
effort
vaccin
good
match
fail
provid
adequ
protect
duda
sinc
fewer
flu
b
case
identifi
compar
flu
case
two
strain
influenza
one
strain
influenza
b
use
current
flu
vaccin
strain
influenza
use
vaccin
good
match
strain
caus
major
flu
ill
unit
state
flu
season
two
illnesscaus
influenza
b
strain
one
strain
well
match
flu
vaccin
therefor
patient
vaccin
season
flu
vaccin
like
well
protect
happen
contract
strain
flu
b
part
vaccin
may
good
protect
accord
center
diseas
control
prevent
flu
vaccin
effect
protect
peopl
flu
midseason
age
group
cdc
number
repres
quit
impress
success
rate
vaccin
howev
consid
emerg
new
season
strain
battl
flu
continu
chang
vaccin
strain
composit
regard
develop
univers
vaccin
capabl
provid
broader
spectrum
protect
diseas
would
greatli
benefit
commun
task
highest
prioriti
tradit
inactiv
live
attenu
vaccin
fairli
effect
protect
popul
season
flu
target
viral
ag
hemagglutinin
ha
howev
case
pandem
caus
new
strain
influenza
high
mortal
rate
human
difficult
produc
adequ
amount
effect
vaccin
time
manner
use
convent
eggbas
product
system
take
least
month
produc
first
vaccin
identif
new
potenti
strain
emanuel
wertheim
virus
extrem
lethal
personnel
requir
biosafeti
level
contain
facil
vaccin
product
virus
replic
well
chicken
embryo
result
low
yield
viru
vaccin
develop
addit
suppli
egg
vaccin
product
might
compromis
pandem
due
high
mortal
affect
chicken
overal
inactiv
live
attenu
vaccin
mildli
immunogen
human
requir
high
dose
ag
multipl
cycl
vaccin
andor
use
adjuv
complic
process
adam
sandrock
rockman
brown
clayvil
furthermor
live
attenu
influenza
vaccin
approv
healthi
peopl
age
exclud
highrisk
popul
gener
licens
platform
manufactur
exist
season
influenza
vaccin
ideal
pandem
scenario
experienc
influenza
pandem
haaheim
et
al
therefor
urgent
explor
altern
vaccin
strategi
pandem
influenza
capabl
prevent
control
infect
time
manner
numer
vaccin
type
eggindepend
product
technolog
mammalian
cellbas
vaccin
recombin
proteinbas
vaccin
viruslik
particlebas
vaccin
dna
vaccin
bacterialvector
vaccin
viralvector
vaccin
comprehens
studi
altern
option
haaheim
et
al
singh
et
al
horimoto
kawaoka
includ
list
possibl
altern
strategi
recombin
ad
vector
vaccin
promis
candid
capabl
induc
rapid
longterm
crossprotect
immun
frequent
evolv
virus
tutykhina
et
al
tang
et
al
vemula
mittal
toro
tang
lamb
comprehens
studi
shown
ad
vectorbas
vaccin
induc
humor
cellular
immun
respons
superior
recombin
protein
vaccin
plasmidbas
dna
vaccin
recombin
vector
system
current
avail
abbink
et
al
naslund
et
al
barefoot
et
al
natur
tropism
vector
respiratori
tract
make
particularli
desir
intranas
inl
vaccin
pathogen
eg
influenza
viru
preferenti
invad
mucosa
inl
immun
adbas
vector
vaccin
use
nasal
spray
could
advantag
sinc
immun
becom
simpl
practic
econom
well
suit
mass
vaccin
plan
context
adbas
vector
well
suit
vaccin
develop
influenza
infect
upper
respiratori
track
effect
adbas
influenza
vaccin
extens
evalu
variou
influenza
viru
subtyp
major
focu
immun
adbas
vaccin
use
differ
rout
dose
regimen
shown
signific
effect
type
strength
induc
immun
respons
holst
et
al
kaufman
et
al
suda
et
al
steitz
et
al
exampl
parenter
administr
associ
diminish
vaccin
efficaci
due
presenc
preexist
antiad
immun
mark
contrast
vaccin
via
altern
rout
shown
overcom
pei
vector
van
kampen
et
al
song
et
al
holman
et
al
appledorn
et
al
xiang
et
al
pandey
et
al
inl
immun
overcom
effect
pei
vector
induc
substanti
immun
respons
encod
ag
provid
protect
challeng
pathogen
mice
rabbit
nonhuman
primat
xiang
et
al
shi
et
al
yu
et
al
croyl
et
al
xu
et
al
richardson
et
al
inl
im
immun
ad
express
ha
protein
ahong
viru
shown
confer
effect
protect
lethal
challeng
heterolog
ahong
avietnam
influenza
virus
absenc
strong
humor
neutral
respons
viru
hoelscher
et
al
studi
thu
demonstr
advector
vaccin
gener
robust
cellular
immun
influenza
benefit
confer
broader
protect
continu
evolv
virus
cellular
immun
respons
likewis
play
import
role
viru
clearanc
promot
earli
recoveri
infect
thoma
et
al
lin
et
al
ad
vaccin
encod
influenza
ha
gene
abl
stimul
crossprotect
immun
differ
subtyp
avian
influenza
viru
toro
et
al
shmarov
et
al
suggest
adbas
vaccin
may
induc
secret
ab
conserv
epitop
ha
molecul
differ
strain
andor
subtyp
du
et
al
provid
crossprotect
diverg
influenza
virus
mount
evid
suggest
adbas
nasal
influenza
vaccin
induc
greater
agspecif
iga
igg
respons
respiratori
tract
vaccin
could
also
provid
virusspecif
activ
cell
lung
better
protect
imadminist
ad
vaccin
shmarov
et
al
park
et
al
price
et
al
signific
mucos
immun
potenti
provid
crossprotect
differ
strain
influenza
hasegawa
et
al
tamura
et
al
ichinoh
et
al
perron
et
al
lau
et
al
gustin
et
al
importantli
immun
respons
found
human
clinic
trial
human
subject
could
safe
effect
immun
advector
nasal
influenza
vaccin
presenc
preexist
immun
van
kampen
et
al
data
recent
yet
unpublish
ad
nasal
vaccin
phase
clinic
studi
involv
patient
ha
glycoprotein
primari
flu
vaccin
target
stimul
higher
level
ha
inhibit
neutral
ab
nab
titer
stronger
cellular
immun
respons
confer
better
protect
homolog
heterolog
viru
challeng
compar
neuraminidas
nucleoprotein
matrix
protein
flu
vaccin
patel
et
al
chen
et
al
nayak
et
al
nevertheless
monoval
ha
adbas
flu
vaccin
may
provid
adequ
protect
broad
rang
heterolog
strain
influenza
virus
current
classifi
ten
antigen
uniqu
clade
basi
phylogenet
analysi
ha
gene
continu
evolut
highli
pathogen
avian
influenza
updat
nomenclatur
sever
strategi
undertaken
broaden
protect
pandem
flu
strain
potenti
pathogen
anim
human
combat
diseas
zhang
strategi
includ
coimmun
multival
ad
vector
express
ha
glycoprotein
ag
deriv
differ
clade
gener
ad
vector
express
ha
protein
na
protein
andor
highli
conserv
influenza
ag
use
rare
ad
serotyp
differ
combin
primeboost
vaccin
adbas
vaccin
strategi
mutual
exclus
test
anim
evalu
efficaci
adbas
vaccin
isol
variou
clade
signific
progress
past
decad
field
ad
vector
flu
vaccin
howev
vaccin
must
circumv
sever
challeng
consid
suitabl
altern
current
licens
vaccin
one
major
drawback
candid
vaccin
must
overcom
licensur
lack
inform
relat
correl
vaccineinduc
immun
diseas
protect
efficaci
mador
et
al
addit
standard
immun
assay
use
assess
innat
adapt
immun
respons
essenti
compar
analysi
vaccin
recent
pei
thought
diminish
vaccin
efficaci
emerg
data
clinic
trial
suggest
limit
overcom
increas
vaccin
dose
catanzaro
et
al
use
inl
rout
vaccin
van
kampen
et
al
howev
clinic
data
need
clarifi
influenc
pei
advector
vaccin
sinc
begin
hiv
epidem
nearli
million
peopl
infect
viru
approxim
million
die
aid
estim
million
peopl
live
hiv
end
decad
effort
seen
dramat
progress
treat
aid
diseas
still
erad
duerr
et
al
current
treatment
option
involv
combin
cocktail
least
three
differ
kind
antiretrovir
agent
howev
result
far
satisfactori
therefor
urgent
need
develop
effect
prevent
treatment
option
aid
context
develop
effect
vaccin
main
focu
govern
academ
institut
industri
worldwid
rapid
increas
prevent
candid
vaccin
hiv
util
variou
strategi
includ
dna
protein
viral
vectorbas
vaccin
gambl
matthew
initi
effort
focus
develop
tradit
firstgener
vaccin
use
inactiv
attenu
hiv
virion
howev
advanc
molecular
engin
genebas
vector
develop
led
emerg
viral
vectorbas
vaccin
elicit
robust
immun
respons
hiv
casimiro
et
al
gener
humor
well
cellular
immun
particularli
involv
ctl
longlast
memori
desir
featur
hiv
vaccin
role
import
nab
well
ctl
respons
prevent
control
hiv
infect
alreadi
demonstr
sha
et
al
among
viralvector
vaccin
candid
tabl
replicationdefect
wide
use
due
proven
efficaci
produc
high
titer
agspecif
ab
strong
ctl
respons
well
high
safeti
intramuscular
im
subcutan
sc
administr
mcelrath
hayn
mcelrath
et
al
sever
clinic
trial
use
vectorbas
vaccin
hiv
multiclad
vaccin
contain
clade
b
gagpolnef
gene
test
phase
merck
priddi
et
al
phase
iib
hvtn
clinic
trial
phase
trial
trival
vaccin
gener
well
toler
induc
cellmedi
immun
respons
peptid
healthi
adult
anoth
multiclad
multival
recombin
contain
clade
b
gagpol
gene
insert
well
envelop
gene
insert
three
major
hiv
clade
b
c
test
phase
clinic
trial
hvtn
peiperl
et
al
vaccin
determin
safe
highli
immunogen
follow
singledos
immun
human
volunt
without
preexist
ad
nab
merck
vaccin
highli
immunogen
induc
narrow
respons
gener
median
tcell
respons
per
particip
hvtn
phase
iib
trial
termin
interim
analysi
show
test
vaccin
neither
reduc
rate
incid
plasma
viremia
infect
buchbind
et
al
extens
work
perform
elucid
potenti
caus
vaccin
failur
although
preliminari
result
suggest
revers
correl
natur
ab
titer
vaccin
efficaci
subsequ
analys
fail
support
correl
obrien
et
al
result
abovement
vaccin
trial
use
two
vaccin
extens
evalu
determin
vaccineinduc
immun
respons
arbitrarili
distribut
across
vaccin
insert
cluster
immunodomin
epitop
hotspot
immunodomin
pattern
observ
trial
differ
vaccinationinduc
epitop
hotspot
overlap
induc
natur
infect
immunodomin
hotspot
correspond
evolutionarili
conserv
region
hiv
genom
epitop
predict
method
use
identifi
hotspot
conclud
observ
immun
respons
cluster
epitop
hotspot
three
vaccin
trial
hotspot
natur
chronic
infect
signific
differ
immunodomin
pattern
reveal
trial
furthermor
trial
differ
observ
even
differ
group
particip
receiv
vaccin
vaccineinduc
immunodomin
hotspot
found
highli
variabl
region
hiv
genom
latter
evid
hiv
vaccin
final
epitop
predict
method
partial
estim
region
vaccineinduc
epitop
hotspot
find
potenti
implic
vaccin
design
suggest
framework
differ
vaccin
candid
compar
earli
phase
evalu
hertz
et
al
addit
posttrial
data
analys
would
inform
design
effect
vaccin
gener
adbas
hiv
vaccin
particular
spite
tremend
progress
design
effect
adbas
vaccin
still
major
drawback
particular
pei
ad
vector
facilit
induct
strong
adspecif
ab
ctl
respons
follow
im
sc
vaccin
administr
result
diminish
express
transgeneencod
ag
compromis
ag
immun
circumv
effect
pei
variou
techniqu
employ
individu
collect
instanc
primeboost
heterolog
vaccin
approach
involv
prime
dna
vaccin
boost
advector
vaccin
shown
great
promis
nabel
lo
et
al
park
et
al
qiu
xu
superior
efficaci
heterolog
primeboost
strategi
homolog
primeboost
approach
elicit
immun
varieti
pathogen
tumor
establish
park
et
al
kim
et
al
schneider
et
al
demonstr
abil
heterolog
primeboost
regimen
induc
respons
park
et
al
number
highli
contagi
infecti
diseas
limit
prevent
therapeut
treatment
potenti
use
weapon
bioterror
boyer
et
al
vaccin
adsechpa
base
human
ad
vector
develop
encod
b
anthraci
protect
ag
pa
induc
host
immun
defens
correspond
pathogen
adsechpa
assess
abil
evok
antipa
immun
respons
protect
mice
lethal
dose
b
anthraci
toxin
comparison
vaccin
base
purifi
pa
protein
combin
commonli
use
adjuv
alhydrogel
rpaalhydrogel
adsechpa
vaccin
develop
protect
immun
respons
immun
mice
faster
rpaalhydrogel
vaccin
day
adsechpaimmun
mice
demonstr
protect
immun
respons
wherea
rpa
alhydrogelimmun
mice
surviv
challeng
studi
abl
demonstr
ad
vector
encod
secret
pa
elicit
rapid
robust
protect
immun
respons
lethal
toxin
primari
mediat
anthrax
pathogenesi
tan
et
al
ag
capsid
incorpor
strategi
see
sect
util
construct
anthraxspecif
ad
vaccin
vector
vector
chimer
hexon
incorpor
b
anthraci
pa
induc
format
paspecif
ab
mice
fail
yield
protect
anthrax
toxin
lethal
factor
challeng
mcconnel
et
al
contrast
find
prior
studi
employ
ag
capsid
incorpor
strategi
demonstr
protect
p
aeruginosa
challeng
worgal
et
al
worgal
et
al
briefli
studi
describ
incorpor
neutral
epitop
p
aeruginosa
outer
membran
protein
f
oprf
hexon
increas
ab
respons
consist
subtyp
balbc
mice
worgal
et
al
furthermor
mice
immun
viru
contain
oprf
epitop
capsid
achiev
surviv
rate
upon
pulmonari
challeng
p
aeruginosa
adbas
vaccin
also
construct
protect
plaguecaus
bacteria
pesti
one
critic
requir
vaccin
plagu
abil
prevent
pesti
effector
protein
enter
macrophag
v
ag
bacteria
play
key
role
process
adbas
vaccin
vector
adsecv
design
encod
ag
fusion
signal
sequenc
extracellular
secret
high
antiv
igg
titer
induc
immun
mice
week
follow
singl
im
administr
vaccin
continu
rise
week
postimmun
singl
im
dose
adsecv
protect
mice
lethal
inl
challeng
pesti
wherea
mice
immun
control
vector
chiuchiolo
et
al
recent
ag
capsid
incorpor
strategi
util
construct
vaccin
vector
protect
pesti
infect
ad
vector
display
pesti
v
ag
capsular
ag
capsid
surfac
elicit
higher
vor
respons
allow
boost
better
protect
lethal
challeng
produc
vaccin
v
protein
convent
adjuv
boyer
et
al
date
one
semisuccess
hiv
prophylact
trial
gambl
matthew
therapeut
hiv
vaccin
could
induc
type
respons
would
invari
decreas
contagi
need
costli
potenti
danger
antiretrovir
treatment
number
opportunist
infect
patient
effect
control
normal
patholog
therapeut
vaccin
would
favor
individu
patient
well
societi
larg
effect
prevent
infect
human
prophylact
vaccin
also
broadli
appeal
utmost
import
beena
et
al
therapeut
hiv
vaccin
design
specif
hivposit
individu
uncompromis
immun
system
capabl
gener
effect
antihiv
immun
respons
therefor
clinic
trial
therapeut
vaccin
recruit
volunt
tcell
count
greater
cell
mm
studi
requir
tcell
count
greater
cellsmm
patient
compromis
immun
system
may
unabl
produc
good
immun
respons
therapeut
hiv
vaccin
therefor
elig
trial
furthermor
trial
requir
therapeut
vaccin
recipi
continu
take
antiretrovir
drug
studi
multidrug
therapi
improv
prognosi
subject
infect
viru
elimin
infect
immunolog
therapi
includ
therapeut
vaccin
need
complement
drug
therapi
search
function
cure
hiv
dermavir
genet
immun
kit
budapest
hungari
mclean
virginia
usa
experiment
hivaid
therapeut
vaccin
combin
three
key
element
ration
therapeut
vaccin
design
singl
pdna
immunogen
express
hiv
ag
synthet
pdna
nanomedicin
formul
dctarget
topic
vaccin
administr
dermavir
alon
combin
antiretrovir
drug
evalu
chronic
sivinfect
macaqu
dermavir
provid
virolog
immunolog
clinic
benefit
sivinfect
macaqu
chronic
hiv
infect
aid
combin
antiretrovir
drug
dermavir
augment
sivspecif
tcell
respons
enhanc
control
viral
load
rebound
treatment
delay
data
also
indic
feasibl
therapeut
immun
even
immunecompromis
host
suggest
dermavir
supplement
antiretrovir
drug
sustain
suppress
replic
lisziewicz
et
al
dermavir
novel
mechan
action
involv
vaccin
transport
epiderm
langerhan
cell
lymph
node
express
pdnaencod
hiv
ag
induc
precursormemori
cell
high
prolifer
capac
effect
consist
demonstr
mous
rabbit
primat
human
subject
safeti
immunogen
preliminari
efficaci
dermavir
clinic
observ
hivinfect
human
subject
dermavir
technolog
platform
dcbase
therapeut
vaccin
might
also
offer
innov
treatment
paradigm
cancer
infecti
diseas
lori
vaccin
cancer
antitumor
potenti
human
ad
discov
soon
isol
row
et
al
observ
tumor
regress
clinic
case
cervic
carcinoma
follow
ad
inocul
howev
ad
emerg
potenti
therapeut
agent
cancer
decad
later
groundbreak
develop
recombin
dna
technolog
sever
clinic
studi
use
ad
vector
cancer
therapi
conduct
past
decad
led
clinic
develop
ad
vectorbas
product
treatment
variou
cancer
advexin
gendicin
encod
wt
tumor
suppressor
control
cytomegaloviru
rou
sarcoma
viru
promot
respect
rati
et
al
remark
gendicin
approv
china
first
gene
therapi
medicin
world
toth
et
al
hybrid
oncolyt
viru
replic
select
cancer
becam
first
engin
replicationselect
viru
use
human
liu
et
al
similar
viru
combin
chemotherapi
approv
chines
state
food
drug
administr
treatment
refractori
nasopharyng
head
neck
cancer
liu
kirn
current
use
human
ad
vector
cancer
therapi
applic
divid
six
major
categori
suicid
gene
therapi
also
known
genedirect
enzym
prodrug
therapi
gdept
suppressor
replac
gene
therapi
rna
interfer
rnai
base
gene
therapi
antiangiogen
therapi
oncolyt
virotherapi
cancer
immunotherapi
briefli
gdept
approach
util
concept
foreign
bacteri
viral
enzymemedi
intracellular
convers
nontox
compound
prodrug
compat
system
administr
cytotox
metabolit
capabl
block
dna
replic
transcriptionprotein
synthesi
target
cancer
cell
upon
vectormedi
deliveri
foreign
enzymeencod
transgen
suicid
gene
due
inabl
cellular
enzym
use
prodrug
substrat
cytotox
effect
achiev
specif
target
cancer
cell
express
deliv
therapeut
transgen
suppressor
replac
rnaibas
therapi
repres
variat
gene
therapi
approach
aim
replac
mutat
inactiv
tumor
suppressor
disrupt
tumorpromot
factor
respect
former
instanc
tumor
suppressor
gene
mutat
mani
cancer
cell
type
replac
function
wt
counterpart
wherea
latter
instanc
disrupt
mrna
encod
tumorpromot
factor
htert
etc
rnai
deliv
context
ad
vector
aim
inhibit
tumor
progress
similarli
antiangiogen
therapi
util
gene
therapi
approach
system
intratumor
deliveri
express
antiangiogen
factor
inhibit
tumor
vasculatur
format
therebi
growth
primari
tumor
metastas
sharma
et
al
contrast
gene
deliverybas
strategi
oncolyt
virotherapi
approach
util
natur
abil
replicationcompet
ad
lytic
destruct
infect
cell
wherebi
intracellularli
produc
viral
progeni
get
releas
infect
cell
spread
around
tumor
mass
consecut
round
ad
replic
cycl
achiev
cancer
target
ad
replic
process
cancer
select
ad
replic
render
two
major
genet
strategi
block
ad
dna
replic
normal
noncanc
malign
cell
involv
engin
mutat
delet
dna
replicationcontrol
immedi
earli
ad
gene
inactiv
crucial
biolog
function
induc
prolifer
infect
cell
see
also
sect
bischoff
et
al
heis
et
al
fueyo
et
al
replac
nativ
promot
gene
tumorspecif
promot
tsp
select
activ
cancer
cell
ko
et
al
ultim
goal
cancer
immunotherapi
elicit
endogen
immun
respons
develop
wellestablish
tumor
ineffect
antitumor
immun
respons
caus
establish
immunosuppress
tumor
microenviron
oncogenesi
indic
immun
system
need
modul
specif
way
effect
suppress
tumor
format
immunotherapi
reli
preform
effector
mechan
well
suit
treatment
establish
tumor
context
cancer
vaccin
base
whole
tumor
cell
dc
puls
tumorassoci
ag
taa
taabas
subunit
vaccin
immun
adjuv
recent
emerg
import
modal
combat
cancer
summari
viral
vectorbas
vaccin
repres
import
treatment
modal
owe
high
practic
valu
versatil
ag
deliveri
robust
natur
adjuvant
intrins
capabl
oncolysi
increas
understand
immun
system
develop
recombin
dna
technolog
led
emerg
innov
vaccin
strategi
notion
cancer
vaccin
could
becom
common
treatment
modal
next
decad
recent
licensur
dcbase
vaccin
proveng
treatment
prostat
cancer
human
along
approv
therapi
oral
melanoma
dog
lend
support
clinic
promis
cancer
vaccin
aurisicchio
ciliberto
adbas
cancer
vaccin
repres
import
rapidli
develop
branch
cancer
vaccinolog
field
ad
vector
emerg
promis
gene
therapi
vector
recombin
vaccin
carrier
owe
wellcharacter
molecular
genet
high
yield
propag
capac
amen
pharmaceut
scale
product
biolog
characterist
choi
yun
mani
studi
shown
adbas
vaccin
effici
gener
antitumor
immun
vaccin
base
deliveri
system
basak
et
al
okur
et
al
howev
pei
human
natur
liver
tropism
substanti
compromis
util
virus
vaccin
develop
hurdl
justifi
implement
variou
strategi
shield
vector
pei
includ
util
altern
ad
serotyp
xenotyp
chimer
ad
vector
hedley
et
al
describ
previou
sect
shield
approach
involv
capsid
genet
chemic
modif
strategi
well
use
vector
conjunct
cellbas
therapi
ex
vivo
preload
dc
administr
had
mucos
surfac
prevent
rapid
vector
clearanc
immun
system
repres
power
altern
vector
shield
approach
bypass
problem
pei
human
popul
altern
serotyp
human
nonhuman
primat
employ
vaccin
develop
human
propos
altern
vaccin
deliveri
low
seropreval
howev
vector
demonstr
lower
immunolog
potenc
compar
vector
mice
nonhuman
primat
similar
result
obtain
barouch
et
al
lemckert
et
al
sinc
pei
human
crossneutr
ovin
chimpanze
canin
porcin
fowl
ad
aurisicchio
ciliberto
nonhuman
ad
speci
capabl
effici
transduc
type
human
murin
cell
cultur
gain
attent
potenti
vector
cancer
vaccin
develop
importantli
cancer
vaccin
base
chimpanze
ad
shown
induc
immun
respons
compar
serotypebas
vector
break
toler
selftumor
ag
overcom
pei
achiev
antitumor
effect
prophylact
cancer
vaccin
util
immunomodulatori
mechan
lead
develop
adapt
immun
respons
taa
import
gener
taaspecif
memori
cell
undergo
rapid
activ
acquisit
effector
function
cancer
cell
express
taa
emerg
host
addit
prophylact
cancer
vaccin
elicit
humor
immun
respons
character
product
taaspecif
ab
latter
may
play
role
contain
primari
tumor
develop
well
prevent
recurr
previous
erad
tumor
howev
pivot
role
vaccinebas
cancer
prevent
belong
taaspecif
ctlbase
cellular
immun
finn
forni
adenovir
vaccin
target
tumorassoci
self
antigen
mani
tumor
ag
simpli
normal
nonmut
tissu
differenti
ag
seen
self
host
immun
system
immun
self
ag
could
induc
autoimmun
tumor
prevent
stimul
taaspecif
immun
break
immunolog
toler
evidenc
numer
transgen
mous
model
overexpress
heterolog
gene
taa
rat
hutchinson
muller
human
cea
kass
et
al
mizobata
et
al
human
carcinomaassoci
mucin
taylorpapadimitri
finn
rows
et
al
deliber
induct
selfreact
use
recombin
viral
vector
shown
result
tumor
destruct
lymphocyt
found
integr
part
process
overwijk
et
al
thu
vaccin
strategi
target
tissu
differenti
self
ag
may
valuabl
preventiontreat
cancer
aris
differenti
cell
tissuesorgan
melanocyt
prostat
testi
breast
ovari
studi
anim
model
demonstr
cancer
vaccin
effect
protect
tumor
challeng
prevent
tumor
occurr
genet
predispos
anim
contrast
cancer
vaccin
shown
limit
therapeut
efficaci
establish
tumor
anim
model
reflect
failur
demonstr
object
antitumor
respons
human
clinic
trial
finn
forni
superior
effect
cancer
prevent
versu
therapi
surpris
given
condit
immun
system
prior
vaccin
neither
impair
tumorand
chemotherapyinduc
suppress
toler
taa
establish
tumor
environ
novel
recombin
vector
base
encod
mous
mesothelin
msln
describ
effect
prophylact
cancer
vaccin
format
metastat
lesion
pancreat
cancer
correspond
mous
tumor
model
intraven
iv
administr
result
msln
deliveri
express
wider
rang
mous
organ
compar
convent
distribut
mainli
liver
spleen
lung
besid
show
reduc
level
liver
transduct
inflammatori
respons
result
reduc
liver
toxic
rel
msln
vaccin
report
enhanc
antitumor
effect
mslnexpress
tumor
via
msln
peptidespecif
tcellmedi
immun
hung
et
al
miyazawa
et
al
line
find
onetim
iv
administr
prevent
growth
primari
tumor
agspecif
manner
also
block
metastas
format
indic
vaccin
promis
approach
stimul
transgeneand
tumorspecif
immun
yamasaki
et
al
guanylyl
cyclas
c
autoantigen
princip
express
intestin
epithelium
univers
primari
metastat
colorect
tumor
immun
ad
express
structur
uniqu
extracellular
domain
ecd
produc
prophylact
therapeut
protect
colon
cancer
metastas
mice
without
collater
autoimmun
snook
et
al
snook
et
al
mechan
protect
involv
lineagespecif
induct
agtarget
cell
without
cell
b
cell
snook
et
al
recombin
ad
vaccin
express
kinaseinact
mutant
form
human
use
immun
balbc
wild
type
wt
transgen
mice
protect
wt
mice
mous
carcinoma
half
transgen
mice
protect
fulli
longterm
prevent
onetim
ip
vaccin
wherea
tumor
growth
mice
eventu
develop
neoplast
lesion
delay
protect
wt
transgen
mice
associ
high
low
level
antibodi
respect
studi
also
evidenc
ctl
induc
wt
transgen
mice
defin
critic
requir
nk
cell
vaccineinduc
protect
tumor
triulzi
et
al
similar
studi
demonstr
vaccin
ad
vector
encod
fulllength
mutationinactiv
nononcogen
kinas
function
result
robust
polyclon
immun
respons
toler
anim
model
translat
strong
effect
antitumor
respons
vivo
hartman
et
al
ad
vector
encod
human
mucin
tumor
antigen
express
breast
pancreat
ovarian
cancer
develop
transduct
dc
specif
stimul
autolog
peripher
blood
lymphocyt
upon
vectormedi
gene
transfer
substanti
improv
ad
rel
liposom
transfect
pecher
et
al
ad
vaccin
encod
taa
mention
see
sect
success
vaccin
develop
infecti
diseas
recent
translat
prophylact
vaccin
viral
induc
neoplasm
us
food
drug
administr
fda
approv
prevent
vaccin
hbv
caus
liver
cancer
two
prophylact
vaccin
hpv
gardasil
cervarix
protect
infect
two
type
hpv
type
close
associ
cervic
head
neck
cancer
hpv
vaccin
deriv
vlp
compos
singl
hpv
protein
altern
genet
vaccin
approach
util
vector
deliveri
express
hpv
hbv
ag
recent
endeavor
well
studi
briefli
describ
follow
exampl
recent
vaccin
strategi
cancer
prevent
cervic
cancer
whose
causal
associ
genit
hpv
infect
firmli
establish
steller
walboom
et
al
remain
lead
caus
cancerrel
mortal
women
gene
highrisk
hpv
type
encod
oncoprotein
capabl
immort
human
keratinocyt
pecoraro
et
al
alter
cell
growth
regul
inactiv
rb
tumor
suppressor
respect
munger
et
al
dyson
et
al
oncoprotein
select
retain
express
cervic
tumor
attract
target
develop
cancer
vaccin
prevent
cervic
cancer
recombin
ad
vector
encod
mutant
cassett
describ
wiek
colleagu
wiek
et
al
promis
vaccin
hpvposit
head
neck
cancer
engin
mutat
render
fulllength
form
nononcogen
preserv
antigen
dosag
mice
inocul
complet
clear
hpvposit
head
neck
squamou
cell
carcinoma
tumor
implant
week
either
intratrach
submucos
ad
vaccin
inocul
signific
product
result
suggest
immun
oncoprotein
effect
method
protect
host
head
neck
squamou
cell
carcinoma
wiek
et
al
nononcogen
vaccin
enhanc
treatment
hpv
express
tumor
calreticulin
crt
abund
kda
ca
bind
protein
local
endoplasm
reticulum
er
consid
relat
hsp
famili
nash
et
al
protein
shown
aid
ag
present
complex
peptid
vitro
elicit
peptidespecif
tcell
respons
basu
srivastava
replicationdefici
ad
vector
express
fusion
gene
construct
achiev
higher
effici
ag
deliveri
improv
ag
present
protein
crt
abil
induc
agspecif
immunotherapeut
activ
tumor
explor
mous
model
vaccin
induc
stronger
immun
respons
ie
tcell
prolifer
product
cytotox
compar
ad
vector
express
alon
vector
provid
complet
protect
mice
challeng
tumor
gener
longterm
immun
memori
control
recurr
importantli
vaccin
tumorbear
mice
result
complet
tumor
regress
tumorbear
anim
taken
togeth
result
demonstr
effect
vaccin
prevent
cervic
tumor
could
potenti
clinic
effect
treatment
alreadi
establish
diseas
gomezgutierrez
et
al
antitumor
immun
also
report
adbas
vaccin
encod
hpv
ectodomain
ecd
human
epitheli
selfag
genet
fuse
acid
ecd
vector
also
contain
human
growth
hormon
signal
sequenc
sig
nterminu
fusion
express
birth
normal
epitheli
cell
diffus
upregul
epitheli
surfac
cancer
breast
ovari
colon
lung
sc
inject
vector
mice
gener
tcelldepend
immun
resist
growth
tumor
year
robust
growth
suppress
syngen
tumor
also
observ
upon
sc
administr
vector
mice
initi
immunolog
unrespons
syngen
cancer
cell
thu
immun
fusion
overcom
anergi
syngen
tumor
transgen
mous
model
zhang
et
al
yet
anoth
protein
fusion
strategi
use
enhanc
hpv
ag
immunogen
fusion
oncoprotein
either
full
truncat
cterminu
hbsag
deliv
context
nonrepl
vector
use
low
immun
dose
infecti
unit
per
dose
hbsag
fusion
protein
assembl
effici
vlp
stimul
ab
respons
carrier
foreign
ag
induc
cytotox
tcell
respons
ab
tcell
respons
case
significantli
stronger
induc
control
ad
vector
express
wildtyp
affect
preexist
immun
either
hbsag
mice
vaccin
vector
encod
develop
ab
ctl
respons
hbsag
howev
ab
igg
titer
higher
hbsag
baezastua
et
al
summari
ad
vector
show
great
potenti
prophylact
cancer
vaccin
immun
viral
induc
neoplasm
hpv
hbv
also
selftaa
due
robust
adjuv
properti
ad
abil
break
immunolog
toler
self
ag
howev
result
induct
autoimmun
may
present
substanti
challeng
treatment
patient
besid
pei
human
effici
liver
uptak
becom
major
obstacl
hadbas
vaccin
due
rapid
clearanc
vector
possibl
toxic
factor
howev
circumv
use
vector
base
altern
ad
serotyp
nonhuman
ad
speci
implement
genet
andor
chemic
ad
shield
technolog
util
altern
mucos
rout
vaccin
deliveri
broad
varieti
deliveri
vehicl
includ
vector
current
evalu
therapeut
vaccin
treatment
establish
tumor
although
mani
approach
fail
gener
signific
therapeut
benefit
clinic
set
efficaci
therapeut
vaccin
gradual
improv
case
result
expand
divers
vaccin
strategi
treatment
combin
therapeut
anticanc
vaccin
evolv
immunotherapi
use
primeboost
tumorspecif
immun
respons
vaccin
typic
use
combin
cancer
therapi
strategi
immunomodul
oncolyt
virotherapi
dctargetingactiv
antiangiogenesi
achiev
clinic
respons
immun
respons
taa
establish
tumor
microenviron
counterbalanc
variou
immun
evas
mechan
regulatori
cell
treg
play
central
role
treg
critic
toler
selfag
play
major
role
determin
effect
anticanc
vaccin
therefor
strategi
target
overcom
variou
immun
evas
mechan
may
work
synergi
therapeut
vaccin
effect
clinic
respons
yaddanapudi
et
al
exampl
recombin
antibodi
cytochemokin
light
costimulatori
ligand
deliv
admedi
gene
transfer
tumor
overcom
immun
evas
mechan
resist
breast
cervic
cancer
model
none
ad
vector
display
signific
therapeut
effect
howev
combin
vector
system
deplet
treg
use
ab
breast
cancer
model
lowdos
cyclophosphamid
cervic
cancer
model
result
signific
tumor
growth
delay
vivo
mediat
nkt
cell
cell
recent
anoth
advanc
improv
efficaci
therapeut
vaccin
made
specif
target
intracellularli
express
taa
exosom
take
advantag
abil
factor
v
like
domain
lactadherin
specif
address
protein
exosom
adenovir
vector
express
extracellular
domain
cea
coupl
domain
demonstr
signific
improv
agspecif
immun
respons
ag
toler
transgen
anim
model
significantli
enhanc
therapeut
antitumor
effect
human
transgen
tumor
model
mice
hartman
et
al
suggest
exosom
target
could
improv
futur
antitumor
vaccin
adbas
cancer
vaccin
often
combin
deliveri
express
taa
along
variou
immunostimulatori
molecul
gmcsf
waldmann
windbichl
et
al
porta
et
al
robertson
ritz
tanaka
et
al
hwang
et
al
wright
et
al
santodonato
et
al
odaka
et
al
khorana
et
al
variou
chemokin
lapteva
et
al
namkoong
et
al
apart
cytokin
chemokin
certain
membranebound
receptor
also
requir
effici
activ
immun
respons
particular
cell
follow
recognit
foreign
ag
context
major
histocompat
complex
mhc
molecul
signal
requir
anoth
signal
signal
deliv
costimulatori
receptor
tnfr
superfamili
activ
two
signal
accompani
third
signal
signal
form
cytokin
cell
receiv
three
signal
undergo
prolifer
acquisit
effector
function
establish
longterm
memori
lanzavecchia
sallusto
ligand
express
apc
choi
et
al
greenfield
et
al
iwakami
et
al
yoshida
et
al
loskog
et
al
tumor
particularli
nonhematopoiet
origin
express
costimulatori
ligand
exploit
lack
costimul
effect
mean
immun
evas
allison
krummel
therefor
use
cancer
vaccin
combin
aforement
immun
modul
potenti
augment
effector
immun
respons
overcom
variou
tumor
immun
evas
mechan
pronounc
antitumor
immun
respons
clinic
benefit
putzer
et
al
choi
et
al
habibagahi
et
al
therapeut
cancer
vaccin
conjunct
oncolyt
viral
vector
see
sect
repres
anoth
attract
cancer
treatment
modal
condit
replic
ad
crad
vector
prove
power
tool
tumor
regress
due
direct
lytic
effect
infect
cancer
cell
also
immun
respons
taa
releas
upon
cradmedi
oncolysi
natur
present
immun
system
macrophag
dc
site
tumor
destruct
thu
replic
ad
vector
especi
oncolyt
vector
arm
transgen
encod
immunomodulatori
factor
play
import
role
adjuv
compon
therapeut
cancer
vaccin
note
howev
express
taa
context
highli
potent
oncolyt
ad
may
alway
optim
vaccin
strategi
potenti
short
durat
transgen
express
cradinfect
cell
due
rapidli
develop
cytopath
effect
lead
oncolyt
cell
destruct
furthermor
attempt
made
augment
immunotherapeut
potenti
oncolyt
ad
vector
incorpor
heat
shock
protein
transgen
sinc
heat
shock
protein
act
chaperon
facilit
protein
fold
transloc
overexpress
cancer
cell
augment
adapt
antitumor
tcell
immun
stimul
process
present
taa
cell
via
apc
wang
et
al
wang
et
al
adbas
vaccin
use
conjunct
apc
particularli
dc
dc
highli
effici
profession
apc
process
load
intracellularli
express
taa
onto
mhc
mhc
ii
molecul
thu
allow
appropri
rel
persist
induct
agspecif
well
tcell
respons
ad
vector
extens
use
transduc
modifi
dc
either
effect
taa
deliveri
present
effector
cell
activ
ie
induct
dcmediat
agspecif
immun
respons
upon
activ
dc
migrat
drain
lymph
node
ln
simultan
upregul
costimulatori
molecul
cytokin
prime
helper
th
ctl
paracort
area
ln
fig
dc
thu
provid
link
innat
adapt
immun
number
studi
demonstr
ex
vivo
transduct
dc
ad
vector
encod
taa
express
dc
result
induct
antitumor
immun
upon
dc
inocul
back
tumorbear
anim
xia
et
al
immun
activ
dc
induc
deliv
immunostimulatori
factor
genet
modif
capsid
fiber
protein
worgal
et
al
instanc
ligand
bind
receptor
highli
express
dc
fig
besid
vector
exhibit
adjuv
effect
capabl
induc
dc
activ
matur
upon
transduct
geutsken
et
al
kanagawa
et
al
anoth
import
advantag
use
dcbase
vaccin
suscept
ex
vivo
treatment
ad
vector
circumv
problem
pei
encount
vivo
human
clinic
trial
howev
treatment
approach
labori
costli
reason
specif
target
dc
vivo
mucos
tissu
skin
may
serv
better
treatment
altern
fig
major
rout
receptordepend
cell
attach
human
ad
involv
car
whose
express
immun
cell
includ
dc
typic
detect
activ
downregul
variou
receptor
express
dc
surfac
dcsign
util
achiev
transduct
retarget
ad
vector
ad
retarget
receptor
would
potenti
allow
effect
specif
transduc
dc
ex
vivo
also
vivo
geijtenbeek
et
al
korokhov
et
al
order
infectivityenhanceretarget
ad
vector
forto
dc
number
fibermodif
strategi
develop
classifi
genet
nongenet
bispecif
adapt
base
new
strategi
combin
two
genet
strategi
tabl
introduc
modif
fiber
protein
ctermin
knob
domain
incorpor
short
peptid
ligand
knobswap
differ
ad
serotyp
fiber
fig
ex
vivo
vivo
strategi
dcbase
vaccin
adbas
vaccin
target
receptor
express
dc
via
fiber
genet
modif
bispecif
conjug
adapt
molecul
combin
thereof
ex
vivo
approach
patientisol
dc
transduc
ad
vaccin
clinic
laboratori
set
treat
matur
factor
infus
back
patient
vivo
vaccin
retarget
advector
vaccin
genet
modifi
fiber
andor
complex
adapt
inject
intraderm
patient
target
dc
natur
environ
lead
antigen
uptak
dc
matur
migrat
lymph
node
dc
activ
cell
gener
ctl
respons
chimera
whole
knob
replac
artifici
fusion
molecul
embodi
essenti
fiber
trimer
motif
receptorbind
motif
see
also
tabl
motif
could
form
target
ligand
fcbind
domain
staphylococcu
aureu
protein
singlechain
ab
scfv
hedley
et
al
affibodi
molecul
given
agbind
specif
fiber
incorpor
knob
shown
improv
dc
transduct
effici
allow
select
deliveri
ag
vitro
vivo
use
human
skin
explant
model
van
de
ven
et
al
de
gruijl
et
al
adapterbas
strategi
util
engin
bispecif
fusion
molecul
bridg
ad
capsid
protein
fiber
target
receptor
dc
see
fig
two
type
engin
bival
adapt
target
receptor
first
type
repres
chemic
conjug
bispecif
ab
consist
fab
fragment
fiber
knobspecif
ab
monoclon
ab
mab
tillman
et
al
second
type
recombin
fusion
solubl
car
scar
mabderiv
singlechain
ab
scfv
pereboev
et
al
hangalapura
et
al
subsequ
latter
adapt
improv
fuse
car
via
trimer
motifcontain
linker
pereboev
et
al
combin
strategi
util
genet
modifi
fiber
fuse
aureu
protein
fcbind
domain
see
conjunct
proteinfus
adapt
compos
fcbind
domain
portion
human
fuse
scfv
deriv
ab
bispecif
adapt
bridg
fibermodifi
ad
particl
receptor
dc
similar
strategi
use
target
dc
via
dcspecif
receptor
dcsign
korokhov
et
al
recent
studi
assess
abil
dcbase
vaccin
induc
longlast
tumorspecif
ctl
respons
either
prophylact
therapeut
applic
spontan
syngen
murin
tumor
model
ricupito
et
al
author
found
prime
dcbase
vaccin
induc
longlast
ctl
respons
wt
mice
homolog
boost
better
sustain
pool
central
memori
cell
associ
potent
protect
melanoma
challeng
appropri
time
booster
vaccin
also
critic
convers
primeboost
vaccin
prove
advantag
even
detriment
therapeut
set
transgen
adenocarcinoma
mous
prostat
tramp
model
respect
result
indic
booster
vaccin
impact
antitumor
immun
differ
extent
depend
applic
prophylact
therapeut
suggest
evalu
need
boost
given
cancer
patient
depend
state
diseas
ricupito
et
al
target
gene
transfer
dc
viral
vector
includ
ad
fall
two
categori
taa
immunomodulatori
protein
cytokin
costimulatori
molecul
varieti
taa
deliv
dc
via
ad
vector
shown
boost
immun
respons
tumor
cell
gallo
et
al
xia
et
al
replicationdefici
recombin
ad
encod
human
melanoma
ag
use
transduc
human
dc
ex
vivo
model
system
cancer
vaccin
therapi
vectortransduc
dc
stimul
tumorinfiltr
lymphocyt
produc
induc
peptidesspecif
mhc
class
irestrict
ctl
within
pbl
normal
donor
vitro
butterfield
et
al
linett
et
al
furthermor
protect
respons
lethal
tumor
challeng
unmodifi
murin
melanoma
cell
observ
upon
vaccin
immunocompet
mice
bone
marrowderiv
murin
dc
transduc
vector
riba
et
al
genet
immun
use
dc
transduc
ex
vivo
express
gene
also
demonstr
induc
tcellbas
immun
breast
tumor
cell
line
overexpress
neu
chen
et
al
augment
abil
dc
present
taa
strategi
dc
modif
allow
constitut
express
immunomodulatori
protein
cytokin
chemokin
develop
dc
genet
modifi
express
tcell
stimulatori
factorscytokin
gmcsf
slc
lymphotactin
could
possess
adjuvantlik
properti
use
treatment
tumor
long
sourc
taa
avail
kirk
mule
combin
immunotherapi
includ
gene
therapi
dc
vaccin
would
advantag
modal
administ
monotherapi
combin
cancer
immunotherapi
may
includ
dcbase
vaccin
admedi
cytokin
gene
therapi
liu
et
al
combin
agspecif
immun
immunostimul
use
interleukin
vaccin
adjuv
wide
use
strategi
therapeut
vaccin
develop
combin
inject
mice
adenovir
vector
carri
either
oncogen
taa
induc
signific
antitumor
immun
known
induc
cellular
immun
respons
suppress
tumor
growth
express
util
andor
ad
protect
tumor
assess
use
anim
tumor
model
protect
effect
combin
significantli
profound
vaccin
alon
also
result
regress
mmsize
tumor
approxim
experiment
anim
compar
vector
control
group
serum
level
ab
product
well
helper
cellprolif
respons
found
significantli
higher
mice
coinfect
experiment
group
receiv
inject
either
vaccin
ctl
respons
exhibit
coinject
group
suggest
tumor
suppress
effect
mediat
primarili
lesser
extent
cell
jin
et
al
anoth
studi
dc
hepatocellular
carcinoma
patient
transduc
ex
vivo
ad
vector
encod
afp
taa
human
gene
show
express
protein
dc
express
afp
enhanc
cytotox
ctl
significantli
increas
product
compar
afpdc
plain
untransduc
dc
control
vivo
data
mous
model
suggest
immun
enhanc
agspecif
antitumor
efficaci
potent
immun
afpdc
individu
find
provid
potenti
strategi
improv
efficaci
dcbase
tumor
vaccin
new
cancer
vaccin
base
truncat
form
survivin
devoid
antiapoptosi
function
tumor
ag
combin
built
test
dna
primerad
boost
regimen
prophylaxi
melanoma
cancer
immun
dna
vaccin
alon
result
weak
immun
respons
modest
antitumor
effect
tumor
inhibit
ratio
upon
dna
vaccin
combin
increas
increas
nearli
radsurvivin
boost
complet
tumor
reject
observ
mice
efficaci
vaccin
administ
therapeut
enhanc
nearli
combin
carboplatin
result
indic
vaccin
truncat
survivin
vaccin
use
dna
primerad
boost
combin
adjuv
carboplatin
repres
attract
strategi
overcom
immun
toler
tumor
hold
potenti
therapeut
benefit
melanoma
therapi
zhao
colleagu
employ
convent
ag
immun
approach
induc
angiogen
effect
tumor
author
use
recombin
encod
vecad
transmembran
glycoprotein
locat
junction
endotheli
cell
vecad
vec
endotheli
cellspecif
cadherin
play
critic
role
regul
process
normal
patholog
angiogenesi
vestweb
hendrix
et
al
liao
et
al
enhanc
ag
deliveri
dc
macrophag
recombin
advec
viru
coupl
ex
vivo
mannan
oxid
condit
mannos
receptor
mr
new
famili
multilectin
receptor
protein
ubiquit
receptor
express
apc
includ
dc
macrophag
addit
role
dctarget
ligand
oxid
mannan
coupl
ad
particl
could
act
immunolog
adjuv
contribut
abil
matur
dc
gener
primari
tcell
respons
zhao
et
al
vaccin
advecmannan
complex
advecm
suppress
tumor
angiogenesi
reduc
densiti
tumor
vasculatur
result
prophylact
therapeut
effect
tumor
growth
prolong
mous
surviv
anim
inject
advecm
develop
vecadspecif
ab
well
ctl
respons
deplet
lymphocyt
vivo
impair
tumor
suppress
activ
advecm
vaccin
suggest
import
role
cytotox
cell
tumor
regress
mechan
zhao
et
al
larg
number
ad
vector
encod
variou
taa
tissu
differenti
ag
viral
agsoncoprotein
develop
date
cancer
vaccin
applic
alon
combin
adjuv
immunomodulatori
molecul
andor
vaccin
type
dna
viral
vector
protein
dc
vaccin
varieti
heterolog
primeboost
vaccin
regimen
exampl
taa
immun
includ
protein
breast
cancer
chen
et
al
epsteinbarr
viru
ebv
nuclear
smith
et
al
chia
et
al
nasopharyng
carcinoma
tightli
associ
ebv
infect
guanylyl
cyclas
c
cancer
mucosa
ag
prevent
primari
metastat
colorect
tumor
snook
et
al
prostatespecif
ag
psa
lubaroff
et
al
combin
protein
fusion
psa
prostat
stem
cell
ag
treatment
prostat
cancer
karan
et
al
cea
treatment
patient
advanc
colorect
cancer
mori
et
al
mors
et
al
combin
diaz
et
al
human
telomeras
revers
transcriptas
htert
liao
et
al
chen
et
al
mani
other
therapeut
efficaci
homolog
heterolog
primeboost
vaccin
strategi
oncofet
antigen
evalu
ali
colleagu
eleg
studi
use
agexpress
replicationdefect
ad
retrovir
transduc
dc
line
subcutan
melanoma
model
vaccin
combin
test
could
provid
signific
tumor
growth
delay
boost
regimen
best
tumor
prophylaxi
demonstr
therapeut
efficaci
mice
establish
tumor
contrast
boost
vaccin
best
regimen
tumor
therapi
author
conclud
prior
immun
condit
mice
induc
immun
respons
sustain
subsequ
boost
contrast
prior
immun
augment
immun
respons
alreadi
induc
tumor
growth
subsequ
vaccin
elicit
tumor
regress
whose
success
depend
alter
polar
immun
respons
interestingli
deplet
treg
tumor
challeng
immun
restor
therapeut
efficaci
ali
et
al
novel
strategi
therapeut
immun
prostat
cancer
use
deliveri
human
prostatespecif
taa
hpsma
dc
ad
vector
recent
propos
william
colleagu
effici
mean
dc
activ
hpsma
present
cell
mous
model
prostat
cancer
develop
author
gener
clonal
deriv
mous
prostat
cancer
cell
line
express
human
psma
maxim
ag
present
dc
express
mhc
class
tap
protein
induc
cell
transduct
anoth
ad
vector
encod
administ
hpsmaexpress
dc
well
direct
intraperiton
inject
vector
result
high
level
tumorspecif
ctl
respons
cell
pretreat
target
significantli
improv
therapeut
antitumor
efficaci
psmaencod
ad
vector
combin
mous
model
human
prostat
cancer
william
et
al
strategi
evalu
phase
iii
clinic
trial
summar
tabl
ag
antigen
final
assur
high
level
clinic
efficaci
field
cancer
vaccin
develop
recent
move
toward
person
ie
patientspecif
approach
exampl
contemporari
cancer
vaccinebas
therapi
recent
fdaapprov
first
ever
vaccin
therapi
cancer
call
sipuleucelt
also
known
commerci
name
proveng
dendreon
inc
although
formul
vaccin
involv
adbas
gene
deliveri
import
mention
regard
underli
approach
clinic
outcom
histor
signific
treatment
approv
cellbas
vaccin
creat
isol
apc
individu
patient
peripher
blood
mononuclear
cell
cultur
fusion
protein
call
consist
pap
prostat
acid
phosphatas
pap
ag
express
major
prostat
cancer
cell
nonprost
tissu
link
cytokin
gmcsf
papgmcsf
apc
cultur
presenc
papgmcsf
display
increas
amount
costimulatori
molecul
surfac
constitut
activ
compon
sipuleucelt
activ
apc
eventu
infus
back
apc
donor
patient
treatment
multicent
random
placebocontrol
clinic
trial
sipuleucelt
increas
overal
surviv
metastat
castrationresist
prostat
cancer
patient
month
howev
fail
induc
tumor
regress
although
exact
therapeut
mechan
remain
elus
treatment
appear
favor
older
patient
downsid
underli
person
approach
make
treatment
labori
technic
complex
extrem
expens
small
et
al
gulley
drake
obstacl
identifi
use
ad
cancer
vaccin
carrier
extens
knowledg
ad
biolog
enabl
research
develop
method
effect
overcom
obstacl
result
ad
vector
move
forefront
tumor
vaccinolog
show
substanti
promis
vehicl
cancer
ag
deliveri
conjunct
oncolyt
therapi
immunotherapi
cellbas
therapi
approach
adbas
vector
except
abil
stimul
cellular
immun
respons
protein
product
transgen
featur
serv
main
impetu
preferenti
use
vector
develop
therapeut
vaccin
past
year
recombin
ad
vector
express
varieti
ag
construct
test
immun
variou
set
howev
ad
infect
induc
pathogen
inflammatori
respons
immunocompet
host
includ
human
even
viral
vector
replic
earli
ad
gene
express
alon
respons
pathogen
reaction
inflamm
consist
earli
phase
play
major
role
late
phase
consist
extens
tcell
respons
ginsberg
imler
addit
pei
ad
major
impedi
vector
deriv
common
human
serotyp
preexist
nab
serotyp
found
human
adult
depend
age
geograph
region
chen
et
al
preexist
nab
limit
addeliv
transgen
express
therebi
reduc
immun
efficaci
vaccin
target
ag
seri
approach
entertain
circumv
neg
impact
preexist
nab
includ
genet
modif
ad
vector
use
isol
differ
speci
chimpanze
fitzgerald
et
al
anoth
strategi
avoid
vector
pei
genet
alter
natur
tropism
vector
improv
select
target
receptor
dc
situ
thu
make
gener
autolog
dc
effici
inexpens
hangalapura
et
al
one
import
featur
adbas
vector
induct
strong
tand
bcell
respons
tcell
respons
long
last
minim
contract
activ
cell
remain
effector
effector
memori
stage
month
although
basi
observ
known
may
reflect
ad
vector
similar
wt
virus
persist
mainli
cell
remain
transcript
activ
ad
vector
also
allow
genet
incorpor
foreign
sequenc
viral
capsid
protein
may
allow
express
gene
product
surfac
repetit
orderli
fashion
therebi
gener
highaffin
bcell
respons
matthew
et
al
pichlagollon
et
al
wu
et
al
noninvas
mucos
vaccin
ad
vector
minim
system
inflamm
preexist
immun
interfer
appreci
potenc
advector
nasal
vaccin
nasal
administr
ad
vector
encod
ag
deriv
select
pathogen
provid
painless
practic
mean
immun
also
gener
rapid
sustain
protect
pathogen
importantli
ad
particl
alon
without
transgen
express
shown
induc
antiinfluenza
state
airway
advector
vaccin
also
use
mass
immun
anim
import
applic
veterinari
medicin
past
two
decad
viru
chimera
technolog
boost
develop
novel
therapeut
ad
applic
gene
therapi
oncolysi
strategi
develop
viru
chimer
address
relev
drawback
clinic
implement
virusbas
therapi
includ
identifi
recent
blood
coagul
factormedi
liver
tropism
ad
waddington
et
al
kalyuzhniy
et
al
safeti
increas
therapeut
effici
clinic
set
alreadi
demonstr
sever
chimer
ad
koski
et
al
pesonen
et
al
new
insight
develop
led
high
number
possibl
combinatori
treatment
modal
deliveri
scheme
call
care
preclin
evalu
relev
ex
vivo
human
model
transit
vivo
tumor
model
clinic
translat
bring
optim
combin
retarget
ad
configur
adjuv
optim
heterolog
primeboost
schedul
clinic
major
effort
term
time
cost
de
gruijl
van
de
ven
consid
promis
approach
adbas
immun
respons
incorpor
heterolog
ag
ad
capsid
dctarget
ad
vaccin
oncolyt
ad
arm
ag
immunomodulatori
transgen
therefor
reason
view
certain
properti
compon
immun
system
alli
rather
enemi
take
advantag
improv
efficaci
cancer
diseasetarget
vaccin
regard
make
part
solut
previous
view
problem
expect
observ
adbas
cancer
vaccin
achiev
clinic
efficaci
year
come
